Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APhIRI II: Alkaline Phosphatase for Ischemia Reperfusion Injury to Prevent Delayed Graft Function
2024-515480-66-01Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), Kidney ischemia reperfusion injury and delayed graft function (DGF) comparing bRESCAP with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Duration of delayed graft function (DGF) by day 28. Planned start May 2023; status: authorised.
02
Drugs
bovine intestinal alkaline phosphatase
03
Conditions
chronic kidney disease (CKD)Kidney ischemia reperfusion injurydelayed graft function (DGF)
Beyond the preview
Go deeper on 2024-515480-66-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515480-66-01.